To hear about similar clinical trials, please enter your email below
Trial Title:
Quality of Life After Gynacological Malignancies
NCT ID:
NCT05692102
Condition:
Gynecologic Cancer
Conditions: Official terms:
Neoplasms
Study type:
Observational
Overall status:
Not yet recruiting
Study design:
Time perspective:
Cross-Sectional
Intervention:
Intervention type:
Other
Intervention name:
Evaluate quality of life after gynaecological malignancies diagnosis and treatment
Description:
diagnosis and treatment
Summary:
Evaluate quality of life after gynaecological malignancies diagnosis and treatment
Detailed description:
gynecological cancers represent 10% of new cancer cases among women The main types are
cervical, endometrial, ovarian and breast cancers. Each of these is unique in terms of
prognosis, treatment, and age at onset.
Early detection and improvement in treatment of these cancers has led to improvements in
survival and, consequently, an increase in the number of survivors However, survival is
accompanied by several negative aspects, such as fatigue, physical changes, sexual
dysfunction, anxiety, and/or depression In addition to the physical and psychological
disorders, survivors of gynecological cancer can experience economic problems related to
work, or access to loans and insurance Although cancer occurs mainly in older adults,
some people, particularly survivors of cervical and ovarian cancer, may experience cancer
at an age where work is still of major importance For these women, a return to work
represents a return to a normal social life and helps them to regain their self-esteem.
Furthermore, work is a source of emotional and financial support and has been shown to
enhance health-related quality of life by its positive effect on self-esteem Therefore,
special attention must be paid to the well-being of survivors of gynecological cancer, as
well as to their social and professional reintegratio is a multidimensional concept which
encom passes physical and mental health as well as social well being. Although in recent
decades, several studies have focused on and its determinants in survivors of
gynecological cancer, has mainly been studied as it pertains to clinical data or with
short follow-up durations. Our previous studies in long-term survivors of breast cancer
have shown that the likelihood that will depend on other factors increases in line with
the length of follow-up since diagnosis.
Due to the improvement in medical science and continuing advancement in early detection
and treatment, the expected survival time of cancer patients has become longer. This has
resulted in an increased interest in exploring the health-related quality of life of
cancer survivors. So, there is a consequent need to satisfy cancer patients' requirements
which would enable them to live a healthy life In many cases, cancer patients experience
sleep disturbance, depression and poor quality of life after being diagnosed and treated
for cancer. So, the assessment of QoL among cancer patients is essential in order to
design interventions for improving patients' outcomes Likewise, QoL assessment assists
people realize how treatment, disease, and health impact quality of life. Furthermore, it
helps to understand potential beneficial and risky aspects of a treatment thus help in
weighing the impact of a decision
Criteria for eligibility:
Study pop:
Eligible women admitted to Assiut University Women health Hospital
Sampling method:
Probability Sample
Criteria:
Inclusion Criteria:.patient diagnosed to have gynaecological cancers by histopathology
2.Adult from 20-70 yrs 3. willing and able to participate 4.Early stage 1-2
Exclusion Criteria:
1pre-existing psychological disorders 2.Stage 4 3.severe medical complications as cardiac
pt 4.Morbid obesity BMI<40
Gender:
Female
Minimum age:
20 Years
Maximum age:
70 Years
Healthy volunteers:
No
Start date:
June 2023
Completion date:
June 2025
Lead sponsor:
Agency:
Assiut University
Agency class:
Other
Source:
Assiut University
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05692102
